The first study to address a World Health Organization (WHO) priority pathogen, gonorrhea, recently found positive preliminary findings that offer hope for patients, particularly in the face of rising antibiotic resistance to current regimens.
If approved, zoliflodacin will be the first new antibiotic for treating 'super-gonorrhea' in decades.
Read More
